The year 2021 will mark the 6th edition of the India Pharmaceutical Forum, an annual flagship event hosted by the Indian Pharmaceutical Alliance. The 6^th IPF will be hosted virtually, entailing seamless accessibility, and is scheduled from 24th February to 26th February 2021. The theme of the 6^th IPF is Patient Centricity: New Paradigm in Quality Management. It focuses on various aspects that define quality management in the pharmaceutical industry, in the post-COVID era, reinstating Patient Centricity as its focus. The three-day conference will bring together dignitaries from the healthcare industry to express their views through discussions ensuing meaningful and actionable outcomes. IPF provides a knowledge-sharing platform to subject-matter experts for facilitating discussions resulting in meaningful and actionable outcomes.

The conference will co inauguration of IPA’s Best Practices document. This will be followed by informative sessions on varied topics under quality management including Inspection during COVID-19 and GDUFA III Negotiation by Mr. David Gaugh, Senior Vice President for Sciences and Regulatory Affairs, AAM. An update on USFDA Quality Standard Control will be presented by Mr. Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, USFDA.

Mr. Sudarshan Jain, Secretary-General, Indian Pharmaceutical Alliance said “COVID-19 has once again reinforced the efforts of the healthcare industry towards a patient-centric approach. This year, the 6th Indian Pharmaceutical Forum will provide an engaging platform to facilitate a comprehensive discussion on the ever-changing shift in quality management, led by significant voices of the industry. It will bring together relevant stakeholders from prominent organisations, leading pharma companies, and regulatory bodies to discuss an action-oriented approach to operate in the future.”

“IPA has always believed that patients across the world should be the centre of any discussion. We are dedicated to highlight and share the best pharmaceutical practices while driving excellence in pharma quality.” Mr. Jain added.

Mr. Satish Reddy, President, Indian Pharmaceutical Alliance said “The Indian pharmaceutical industry effectively rose to the challenges of COVID-19 and reinstated its potential in the global pharma landscape. Maintaining benchmark quality standards is pivotal for all Indian Pharmaceutical Alliance (IPA) member companies. IPA is committed towards driving excellence in quality and safety standards and the 6th Indian Pharmaceutical Forum (IPF) is a step ahead to showcase the collaborative approach of the industry towards quality management while addressing evolving patient needs.” commence with a Keynote address by Ms. S Aparna, Secretary, Department of Pharmaceuticals, and The forum will also encompass five-panel discussions on contemporary subjects such as New Paradigm in Quality Management, Digitisation/Automation, and AI in operations and more. The last day will be concluded with a special panel discussion comprising CEOs of leading Indian Pharma companies such as Cadila Healthcare, Cipla, Dr. Reddy’s, Lupin, Sun Pharma, and Torrent Pharma to deliberate on ‘The impact of COVID-19 on pharmaceutical industry’.